In amyotrophic lateral sclerosis, there is a need for biomarkers to distinguish patients from controls, to follow disease progression and to provide information about the pathogenesis of disease. In a
Note. The estimate of the effect of MMN represents the estimate of the difference in cognitive scores between participants who received IFA and MMN, expressed as a fraction of the variation (standard
